Encision Reports First Quarter Fiscal Year 2018 Results

Encision Reports First Quarter Fiscal Year 2018 Results

PR Newswire

BOULDER, Colo., July 27, 2017 /PRNewswire/ -- Encision Inc. (ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2018 first quarter that ended June 30, 2017.

The Company posted quarterly net revenue of $2.36 million for a quarterly net income of $181 thousand, or $0.02 per share. These results compare to net revenue of $2.28 million for a quarterly net loss of $99 thousand, or $(0.01) per share, in the year-ago quarter. Gross margin on net revenue was 57% in the fiscal 2018 first quarter and 52% in the fiscal 2017 first quarter. Net revenue for the current quarter included net revenue of $255 thousand from an order for non-AEM product. Gross margin on net revenue was higher in the current quarter as a result of product mix and lower costs in manufacturing operations.

Net cash of $108 thousand was generated by operations in the current quarter compared to net cash of $128 thousand used in operations in last year's quarter.

"We are pleased to have achieved profitability in the current quarter," said Greg Trudel, President and CEO. "We began selling our next-generation AEM® Burn Protection Cable and our next-generation durable monitors at the end of the quarter. Our next-generation durable monitor will make AEM® Safety adoption even more attractive for our customers and drive new levels of performance and growth. In our second quarter, we expect to complete the order for non-AEM product for additional net revenue of approximately $245 thousand. We expect that the second quarter will be profitable."

Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2017 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:

Mala Ray, Encision Inc., 303-444-2600, [email protected]

 

Encision Inc.

Unaudited Condensed Statements of Operations

(in thousands, except per share information)




Three Months Ended



June 30, 2017


June 30, 2016

Net revenue


$2,364


$2,277

Cost of revenue


1,020


1,087

Gross profit


1,344


1,190

Operating expenses:





    Sales and marketing


601


629

    General and administrative


324


344

    Research and development


221


302

        Total operating expenses


1,146


1,275

Operating income (loss)


198


(85)

Interest and other expense, net


(17)


(14)

Income (loss) before provision for income taxes


181


(99)

Provision for income taxes


––


––

Net income (loss)


$181


$  (99)

Net income (loss) per share—basic and diluted


$ 0.02


$(0.01)

Weighted average number of shares—basic
   and diluted


10,683


10,673

 

Encision Inc.

Unaudited Condensed Balance Sheets

 (in thousands)




June 30, 2017


March 31, 2017

ASSETS





Cash and cash equivalents


$    79


$    45

Restricted cash


25


50

Accounts receivable, net


984


1,042

Inventories, net


1,200


1,129

Prepaid expenses


122


62

    Total current assets


2,410


2,328

Equipment, net


439


468

Patents, net


263


254

Other assets


17


17

    Total assets


$ 3,129


$ 3,067

LIABILITIES AND SHAREHOLDERS'
EQUITY





Accounts payable


$  394


$   403

Accrued compensation


212


268

Other accrued liabilities


254


248

Line of credit


207


275

Deferred rent


30


30

    Total current liabilities


1,097


1,224

Deferred rent


33


41

    Total liabilities


1,130


1,265

Common stock and additional paid-in capital


23,767


23,752

Accumulated (deficit)


(21,768)


(21,950)

    Total shareholders' equity


1,999


1,802

    Total liabilities and shareholders' equity


$ 3,129


$ 3,067

 

Encision Inc.

Unaudited Condensed Statements of Cash Flows

 (in thousands)




Three Months Ended



June 30, 2017


June 30, 2016

Operating activities:





    Net income (loss)


$ 181


$  (99)

    Adjustments to reconcile net income (loss) to cash

        generated by (used in) operating activities:





    Depreciation and amortization


52


60

    Share-based compensation expense


15


17

    Recovery from doubtful accounts, net


(15)


(1)

    Provision for (recovery from) inventory obsolescence, net


10


(8)

    Changes in operating assets and liabilities:





        Accounts receivable     


73


(105)

        Inventories


(82)


29

        Prepaid expenses and other assets


(60)


(77)

        Accounts payable


(9)


88

        Accrued compensation and other accrued liabilities


(57)


(32)

            Net cash generated by (used in) operating activities


108


(128)






Investing activities:





    Acquisition of property and equipment


(16)


(25)

    Patent costs


(15)


(14)

            Net cash used in investing activities


(31)


(39)






Financing activities:





    Paydown of credit facility, net change


(68)


(79)

    Change in restricted cash


25


--

            Net cash used in financing activities


(43)


(79)






Increase (decrease) in cash and cash equivalents


34


(246)

Cash and cash equivalents, beginning of period


45


293

Cash and cash equivalents, end of period


$    79


$ 47

 

View original content:http://www.prnewswire.com/news-releases/encision-reports-first-quarter-fiscal-year-2018-results-300494880.html

SOURCE Encision Inc.

Copyright CNW Group 2017